問卷

TPIDB > Search Result

Search Result

篩選

List

138Cases

2025-12-04 - 2028-12-23

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting5Sites

2025-12-04 - 2029-12-24

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting7Sites

2026-02-06 - 2032-09-25

Phase III

Not yet recruiting
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2026-02-12 - 2033-10-12

Phase III

Not yet recruiting
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
9Sites

Not yet recruiting1Sites

Recruiting8Sites

2026-03-16 - 2029-01-31

Phase III

Not yet recruiting
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting2Sites

Recruiting10Sites

2026-05-01 - 2027-12-31

Phase II

Active
A Phase 2b, Randomized, Placebo‑Controlled Study with Long-term Re-Treatment to Evaluate the Efficacy, Safety, and Tolerability of CBL‑514 Injection for Reducing Abdominal Subcutaneous Fat
  • Condition/Disease

    Subcutaneous Fat

  • Test Drug

    CBL-514

Participate Sites
8Sites

Recruiting8Sites

2025-02-20 - 2027-10-29

Phase II

Not yet recruiting
Innovative Trial Interventional Therapies and Combinations for Colorectal Cancer: Key Program for Participants
  • Condition/Disease

    Colorectal cancer

  • Test Drug

    MEDI5752

Participate Sites
4Sites

Recruiting4Sites

2025-03-01 - 2030-06-30

Active
A phase III, randomized, double-blind, placebo-controlled, event-driven trial was conducted to evaluate the effect of Baxdrostat in combination with Dapagliflozin compared to Dapagliflozin alone on the risk of first-time heart failure and cardiovascular death in participants at high risk of developing heart failure.
  • Condition/Disease

    The time elapsed before the first occurrence of any of the following events: • Hospitalization due to HF • Non-hospitalized HF • Death due to CV

  • Test Drug

    Baxdrostat Dapagliflozin

Participate Sites
18Sites

Recruiting18Sites